After the treatment period, one cohort of mice was sacrificed to measure the human leukemia burden in the bone marrow and spleen using antibodies against human AML immunophenotypic cell surface markers (hCD45+, CD13+, CD33+). This evidence concerns the gene CD33 and leukemia.